A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

Recruiting

Phase 1

EDP-978A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

Sponsor:

Enanta Pharmaceuticals, Inc

Code:

NCT07540910

Conditions

Chronic Inducible Urticaria

Chronic Spontaneous Urticaria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

EDP-978

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-07. This information was provided to ClinicalTrials.gov by Enanta Pharmaceuticals, Inc on 2026-04-21.